Review: 5-HT3 Receptor Antagonists Cut Peri-Op Shivering

This article originally appeared here.
Share this content:
Review: 5-HT<sub>3</sub> Receptor Antagonists Cut Peri-Op Shivering
Review: 5-HT3 Receptor Antagonists Cut Peri-Op Shivering

TUESDAY, Sept. 27, 2016 (HealthDay News) -- 5-HT3 receptor antagonists (5-HT3RAs) seem to be effective for preventing perioperative shivering (POS), according to a review and meta-analysis published online Sept. 15 in the Journal of Clinical Pharmacology.

Wen Wang, from the Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing, and colleagues reviewed the results of randomized trials examining the preventive efficacy and safety of 5-HT3RA on POS. Data from 16 studies with 1,126 patients were included in a meta-analysis.

The researchers found that intravenous administration of 5-HT3RAs significantly reduced the incidence of POS (risk ratio [RR], 0.44; 95 percent confidence interval [CI], 0.35 to 0.56) and of postoperative nausea and vomiting (RR, 0.52; 95 percent CI, 0.28 to 0.97) compared with the control group. 5-HT3RAs were not superior for lowering the rate of bradycardia (RR, 0.75; 95 percent CI, 0.38 to 1.49) or hypotension (RR, 0.79; 95 percent CI, 0.44 to 1.43).

"More high-quality of randomized controlled trials with larger sample size are still required to draw a definite conclusion about the preventive efficacy of 5-HT3RAs on POS prevention in the future," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »